Keegan S Johnson1, David S Chu. 1. Department of Ophthalmology, New Jersey Medical School-University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103, USA.
Abstract
PURPOSE: To suggest that sub-Tenon triamcinolone acetonide (TA) injections may be a helpful supplement in patients with scleritis. DESIGN: Retrospective, interventional case series. METHODS: A retrospective chart review was conducted of all patients at our institution receiving sub-Tenon TA injections for scleritis between August 2001 and August 2007. Outcome measures included subjective improvement, presence of inflammation, and adverse events. RESULTS: Eleven patients (12 eyes) were included in this study. The mean age was 50 years; 2 patients were male and 9 female. Six patients had systemic autoimmune disease. All patients were receiving systemic medications for scleritis at the time of injection. Mean initial follow-up time was 3 weeks. Ten of 11 patients reported subjective improvement, and 10 patients had improvement in objective inflammation. Three patients had adverse side effects, including ocular hypertension, worsening of cataract, and subconjunctival hemorrhage with periorbital ecchymosis. CONCLUSIONS: Sub-Tenon TA injections may be a useful adjunct to achieving transient, partial improvement of subjective pain and objective inflammation in patients with scleritis while awaiting systemic medications to take effect. Adverse events were manageable in this small series. Copyright 2010. Published by Elsevier Inc.
PURPOSE: To suggest that sub-Tenon triamcinolone acetonide (TA) injections may be a helpful supplement in patients with scleritis. DESIGN: Retrospective, interventional case series. METHODS: A retrospective chart review was conducted of all patients at our institution receiving sub-Tenon TA injections for scleritis between August 2001 and August 2007. Outcome measures included subjective improvement, presence of inflammation, and adverse events. RESULTS: Eleven patients (12 eyes) were included in this study. The mean age was 50 years; 2 patients were male and 9 female. Six patients had systemic autoimmune disease. All patients were receiving systemic medications for scleritis at the time of injection. Mean initial follow-up time was 3 weeks. Ten of 11 patients reported subjective improvement, and 10 patients had improvement in objective inflammation. Three patients had adverse side effects, including ocular hypertension, worsening of cataract, and subconjunctival hemorrhage with periorbital ecchymosis. CONCLUSIONS: Sub-Tenon TA injections may be a useful adjunct to achieving transient, partial improvement of subjective pain and objective inflammation in patients with scleritis while awaiting systemic medications to take effect. Adverse events were manageable in this small series. Copyright 2010. Published by Elsevier Inc.
Authors: Elliott H Sohn; Robert Wang; Russell Read; Athena Roufas; Livia Teo; Ramana Moorthy; Thomas Albini; Daniel V Vasconcelos-Santos; Laurie D Dustin; Ehud Zamir; Soon-Phaik Chee; Peter McCluskey; Ronald Smith; Narsing Rao Journal: Ophthalmology Date: 2011-06-25 Impact factor: 12.079
Authors: Nirali Bhatt; Monica Dalal; William Tucker; Dominic Obiyor; Robert Nussenblatt; H Nida Sen Journal: Am J Ophthalmol Date: 2014-12-17 Impact factor: 5.258